Identification
Instrument name
GENSIGHT BIOLOGICS
Symbol
SIGHT
ISIN code
FR0013183985
Exchange / Market
Euronext
Trading location
Paris
Products family
Stocks
Capitalization compartment
Compartment C
ICB
Biotechnology
Operation
IPO date
IPO price
EUR 8.00
Issue type
Initial Public offering
Catégorie
IPO
Price range
EUR 7.80 - EUR 9.20

Company profile

GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2019, the company had a portfolio of 2 products, including 1 in phase III clinical development (GS010 for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis pigmentosa).

Source: Cofisem - Last Update: 15 Apr 2020
Key Executives
Chief Executive Officer Bernard Gilly
Administrative & Finance Director Thomas Gidoin
Source: Cofisem - Last Update: 03 Jun 2019
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales 700
Income from ordinary activities 700
Operating income -30,298 -33,045 -23,990 -22,019 -13,661
Cost (net) of financial indebtedness
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -30,710 -33,453 -24,112 -22,082 -13,654
Net income (Group share) -30,710 -33,453 -24,112 -22,082 -13,654
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 15 Apr 2020
Shareholder information
Flottant 33.01 %
Sofinnova Crossover I SLP 17.09 %
Versant 11.42 %
Strategic International Group Limited 6.43 %
Bpifrance Participations 6.09 %
Abingworth Bioventures 4.88 %
Novartis Pharma 4.84 %
Vitavest 4.66 %
Bpifrance Investissement 2.97 %
Bernard Gilly 2.95 %
Employees 0.84 %
Source: Cofisem - Last Update: 03 Jun 2019